Replies to post #10423 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

NovoSeven Growth Continues



DKK 1600M = $330M ($1.3B annualized rate)

NovoSeven is a blockbuster, but continued growth at a
high rate is problematic due to the colossal cost per dose.
Lowering production cost is the impetus for GTC’s rFVIIa
program with LFB.

Source of graphic: Novo Nordisk